HBHans-Jörg Bühring

Hans-Jörg Bühring

*This is an algorithmically generated author record based on publicly available information.

Hans-Jörg Bühring has a total of 80 co-authors. Here are the top co-authors by number of shared publications:

  • Kavitha Sivasubramaniyan

    Division of Hematology, Immunology, Oncology, Rheumatology and Pulmonology, Department of Internal Medicine II, University Clinic of Tübingen , Tübingen, Germany

    5 shared publications
  • Sabrina Treml

    University Clinic of Tübingen

    5 shared publications
  • Abhishek Harichandan

    Division of Hematology, Immunology, Oncology, Rheumatology and Pulmonology, Department of Internal Medicine II, University Clinic of Tübingen , Tübingen, Germany

    4 shared publications
  • Arnulf Stenzl

    Department of Urology, University Clinic of Tübingen , Tübingen, Germany

    3 shared publications
  • Jörg Hennenlotter

    Department of Urology, University Clinic of Tübingen , Tübingen, Germany

    3 shared publications
  • Lothar Kanz

    Department of Internal Medicine II, Division of Hematology, Immunology, Oncology, Rheumatology and Pulmonology , University Clinic of Tübingen , Tübingen , Germany

    3 shared publications

Latest Publications

  • Open Access

    Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody

    by Bastian J. Schmied, Martina S. Lutz, Fabian Riegg, Latifa Zekri, Jonas S. Heitmann, Hans-Jörg Bühring, Gundram Jung, Helmut R. Salih

    Antibody-dependent cellular cytotoxicity (ADCC) is a major mechanism by which antitumor antibodies mediate therapeutic efficacy. At present, we evaluate an Fc-optimized (amino acid substitutions S239D/I332E) FLT3 antibody termed 4G8-SDIEM (FLYSYN) in patients with acute myeloid leukemia (NCT02789254). Here we studied the possibility to induce NK cell ADCC against B-cell acute lymphoblastic leukemia (B-ALL) by Fc-optimized FLT3 antibody treatment. Flow cytometric analysis confirmed that FLT3 is widely expressed on B-ALL cell lines and leukemic cells of B-ALL patients. FLT3 expression did not correlate with that of CD20, which is targeted by Rituximab, a therapeutic monoclonal antibody (mAb) employed in B-ALL treatment regimens. Our FLT3 mAb with enhanced affinity to the Fc receptor CD16a termed 4G8-SDIE potently induced NK cell reactivity against FLT3-transfectants, the B-ALL cell line SEM and primary leukemic cells of adult B-ALL patients in a target-antigen dependent manner as revealed by analyses of NK cell activation and degranulation. This was mirrored by potent 4G8-SDIE mediated NK cell ADCC in experiments with FLT3-transfectants, the cell line SEM and primary cells as target cells. Taken together, the findings presented in this study provide evidence that 4G8-SDIE may be a promising agent for the treatment of B-ALL, particularly in CD20-negative cases.


  • Open Access

    An Fc-Optimized CD133 Antibody for Induction of Natural Killer Cell Reactivity Against Colorectal Cancer

    by Bastian J. Schmied, Fabian Riegg, Latifa Zekri, Ludger Grosse-Hovest, Hans-Jörg Bühring, Gundram Jung, Helmut R. Salih

    The introduction of monoclonal antibodies (mAbs) has largely improved treatment options for cancer patients. The ability of antitumor mAbs to elicit antibody-dependent cellular cytotoxicity (ADCC) contributes to a large extent to their therapeutic efficacy. Many efforts accordingly aim to improve this important function by engineering mAbs with Fc parts that display enhanced affinity to the Fc receptor CD16 expressed, e.g., on natural killer (NK) cells. Here we characterized the CD133 mAb 293C3-SDIE that contains an engineered Fc part modified by the amino acid exchanges S239D/I332E—that reportedly increase the affinity to CD16—with regard to its ability to induce NK reactivity against colorectal cancer (CRC). 293C3-SDIE was found to be a stable protein with favorable binding characteristics achieving saturating binding to CRC cells at concentrations of approximately 1 µg/mL. While not directly affecting CRC cell growth and viability, 293C3-SDIE potently induced NK cell activation, degranulation, secretion of Interferon-γ, as well as ADCC resulting in potent lysis of CRC cell lines. Based on the preclinical characterization presented in this study and the available data indicating that CD133 is broadly expressed in CRC and represents a negative prognostic marker, we conclude that 293C3-SDIE constitutes a promising therapeutic agent for the treatment of CRC and thus warrants clinical evaluation.


  • Molecular Signatures of Primary Human Spermatogonial Progenitors and Its Neighboring Peritubular Stromal Compartment

    by Abhishek Harichandan, Kavitha Sivasubramaniyan, Jörg Hennenlotter, Sven Poths, Jens Bedke, Stephan Kruck, Arnulf Stenzl, Hans-Jörg Bühring

    In-depth understanding of human spermatogenesis requires studying specific molecular signatures and interactions of spermatogonia with other testicular cell populations, for which isolation of pure populations of different cell types is crucial. Here, we describe a technique to simultaneously enrich pure, multiple testicular cell populations, including spermatogonia, endothelial (TECs), and perivascular mesenchymal stem/stromal cells (TMSCs), from testicular tissue by flow cytometry using a combination of defined markers. Immunohistochemical studies, multicolor staining, and cell sorting followed by multiplex quantitative real-time polymerase chain reaction (qRT-PCR) analysis revealed that spermatogonia were highly enriched in the CD49f+CD49a−HLA-ABC−SSEA-4+ fraction of primary testicular cells. In contrast to spermatogonia, TMSCs and TECs were highly enriched in the CD49f+CD49a+HLA-ABC+CD144− and CD49f+CD49a+HLA-ABC+CD144+subsets, respectively. The delineation was confirmed by the expression of specific stromal and endothelial key markers as well as by the differentiation and angiogenic capacity of the sorted populations. In this article, for the first time, we performed transcriptome profiling of highly enriched, freshly isolated human spermatogonia and compared their expression profile with that of TMSCs. Our RNA sequencing data favor the hypothesis that TMSCs are candidate niche components for spermatogonia. The composite genotype and phenotype of defined testicular cell populations combined with a robust isolation procedure from small biopsies contributes to a better understanding of cellular interactions and for the establishment of efficient culture techniques to maintain spermatogonial progenitors.


  • Open Access

    Profiling of primary peripheral blood‐ and monocyte‐derived dendritic cells using monoclonal antibodies from the HLDA10 Workshop in Wollongong, Australia

    by Stella E Autenrieth, Sabrina Grimm, Susanne Malaika Rittig, Frank Grünebach, Cécile Gouttefangeas, Hans‐Jörg Bühring

    Dendritic cells (DCs) arise from hematopoietic stem cells and develop into a discrete cellular lineage distinct from other leucocytes. Mainly three phenotypically and functionally distinct DC subsets are described in the human peripheral blood (PB): plasmacytoid DCs (pDCs), which express the key marker CD303 (BDCA‐2), and two myeloid DC subsets (CD1c+ DC (mDC1) and CD141+ DC (mDC2)), which express the key markers CD1c (BDCA‐1) and CD141 (BDCA‐3), respectively. In addition to these primary cell subsets, DCs can also be generated in vitro from either CD34+ stem/progenitor cells in the presence of Flt3 (Fms‐related tyrosine kinase 3) ligand or from CD14+ monocytes (monocyte‐derived DCs (mo‐DCs)) in the presence of granulocyte–macrophage colony‐stimulating factor+interleukin‐4 (GM‐CSF+IL‐4). Here we compare the reactivity patterns of HLDA10 antibodies (monoclonal antibody (mAb)) with pDCs, CD1c+ DCs and CD141+ DCs, as well as with CD14+‐derived mo‐DCs cultured for 7 days in the presence of 100 ng/ml GM‐CSF plus 20 ng/ml IL‐4. A detailed profiling of these DC subsets based on immunophenotyping and multicolour flow cytometry analysis is presented. Using the panel of HLDA10 Workshop mAb, we could verify known targets selectively expressed on discrete DC subsets including CD370 as a selective marker for CD141+ DCs and CD366 as a marker for both myeloid subsets. In addition, vimentin and other markers are heterogeneously expressed on all three subsets, suggesting the existence of so far not identified DC subsets.


  • Open Access

    Expression of stage-specific embryonic antigen-4 (SSEA-4) defines spontaneous loss of epithelial phenotype in human solid tumor cells

    by Kavitha Sivasubramaniyan, Abhishek Harichandan, Karin Schilbach, Andreas F Mack, Jens Bedke, Arnulf Stenzl, Lothar Kanz, Gerhard Niederfellner, Hans-Jörg Bühring

    Stage-specific embryonic antigen-4 (SSEA-4) is a glycosphingolipid, which is overexpressed in some cancers and has been linked to disease progression. However, little is known about the functions of SSEA-4 and the characteristics of SSEA-4 expressing tumor cells. Our studies identified SSEA-4 expression on a subpopulation of cells in many solid tumor cell lines but not in leukemic cell lines. Fluorescence-activated cell sorting-sorted SSEA-4+ prostate cancer cells formed fibroblast-like colonies with limited cell–cell contacts, whereas SSEA-4− cells formed cobblestone-like epithelial colonies. Only colonies derived from SSEA-4+ cells were enriched for pluripotent embryonic stem cell markers. Moreover, major epithelial cell-associated markers Claudin-7, E-cadherin, ESRP1 and GRHL2 were down-regulated in the SSEA-4+ fraction of DU145 and HCT-116 cells. Similar to cell lines, SSEA-4+ primary prostate tumor cells also showed down-regulation of epithelial cell-associated markers. In addition, they showed up-regulation of epithelial-to-mesenchymal transition as well as mesenchymal markers. Furthermore, SSEA-4+ cells escape from adhesive colonies spontaneously and form invadopodia-like migratory structures, in which SSEA-4, cortactin as well as active pPI3K, pAkt and pSrc are enriched and colocalized. Finally, SSEA-4+ cells displayed strong tumorigenic ability and stable knockdown of SSEA-4 synthesis resulted in decreased cellular adhesion to different extracellular matrices. In conclusion, we introduce SSEA-4 as a novel marker to identify heterogeneous, invasive subpopulations of tumor cells. Moreover, increased cell-surface SSEA-4 expression is associated with the loss of cell–cell interactions and the gain of a migratory phenotype, suggesting an important role of SSEA-4 in cancer invasion by influencing cellular adhesion to the extracellular matrix.


  • Open Access

    Update on canine MSC markers

    by Marianna A. Tryfonidou, Susanne Schumann, Sorin Armeanu, Abhishek Harichandan, Kavitha Sivasubramaniyan, Jürgen Mollenhauer, Hans-Jörg Bühring


  • Open Access

    Isolation of adult human spermatogonial progenitors using novel markers

    by Abhishek Harichandan, Kavitha Sivasubramaniyan, Jörg Hennenlotter, Christian Schwentner, Arnulf Stenzl, Hans-Jörg Bühring


  • Surface CD24 distinguishes between low differentiated and transit‐amplifying cells in the basal layer of human prostate

    by Neli Petkova, Jörg Hennenlotter, Malgorzata Sobiesiak, Tilman Todenhöfer, Marcus Scharpf, Arnulf Stenzl, Hans‐Jörg Bühring, Christian Schwentner

    BACKGROUND: Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are common abnormalities in elderly men. It is considered that epithelial stem cells are involved in the etiology and development of both diseases. To distinguish aberrant from normal cells, the knowledge about primary epithelial stem/progenitor cells (ES/P) is essential. The aim of this study was to examine the role of surface markers to distinguish between different subsets of prostate basal epithelium.METHODS: The expression pattern of prostate tissue single cell suspensions was analyzed by flow cytometry using different markers. Sorted cell populations were examined for their clonogenic capacity and the resulted colonies were analyzed with flow cytometry, Western blot, and qPCR for stem cell, basal, and luminal epithelium markers. Additionally, the histological localization of the examined markers was determined using immunofluorescence.RESULTS: Using the combination of CD49f, Trop‐2, and surface CD24, basal cell subsets with distinct differentiation capacities were dissected (CD49f+Trop‐2+CD24− and CD49f+Trop‐2+CD24+). Although cells from the two subsets gave rise to similar basal colonies, qPCR of primary tissue revealed that higher levels of basal marker expression were detected in the CD49f+Trop‐2+CD24− subset. Immunofluorescence analysis showed a prominent expression of CD24 by luminal and basal cells.CONCLUSIONS: Subsets with distinct differentiation capacities within the basal epithelium (CD49f+Trop‐2+CD24− and CD49f+Trop‐2+CD24+) can be distinguished in human prostate. CD24 is a marker expressed on the basal transit‐amplifying cells (transition cells) and may play a role in the differentiation and migration of ES/P cells to the luminal layer. The knowledge of this mechanism is of relevance for treatment of both diseases. Prostate 73: 1576–1590, 2013


  • Prospective Isolation and Characterization of Human Bone Marrow-Derived MSCs

    by A. Harichandan, K. Sivasubramaniyan, H.-J. Bühring

    There is an increasing interest in adult stem cells, especially mesenchymal stem/stromal cells (MSCs), in hematology and regenerative medicine because of the simplicity of isolation and ex vivo expansion of these cells. Conventionally, MSCs are functionally isolated from tissue based on their capacity to adhere to the surface of culture flasks. This isolation procedure is hampered by the unpredictable influence of secreted molecules and interactions with co-cultured hematopoietic and other unrelated cells, as well as by the arbitrarily selected removal time of non-adherent cells prior to the expansion of MSCs. Finally, functionally isolated cells do not provide biological information about the starting population. To circumvent these limitations, several strategies have been developed to facilitate the prospective isolation of MSCs based on the selective expression or absence of surface markers. The isolation and ex vivo expansion of these cells require an adequate quality control of the source and product. Here we summarize the most frequently used markers and introduce new targets for antibody-based isolation and characterization of bone marrow-derived MSCs.


  • The Mesenchymal Stem Cell Antigen MSCA-1 is Identical to Tissue Non-specific Alkaline Phosphatase

    by Malgorzata Sobiesiak, Kavitha Sivasubramaniyan, Clemens Hermann, Charmaine Tan, Melanie Örgel, Sabrina Treml, Flavianna Cerabona, Peter de Zwart, Uwe Ochs, Claudia A. Müller, et al.

    We have recently identified 2 distinct CD271 bright MSCA-1 dim CD56 + and CD271 bright MSCA-1 bright CD56 − MSC subsets in primary femur-derived bone marrow (BM), which differ in their expression pattern and morphology as well as in their clonogenic and differentiation capacity. Here, we show that MSCA-1 is identical to tissue non-specific alkaline phosphatase (TNAP), an ectoenzyme known to be expressed at high levels in liver, bone, and kidney as well as in embryonic stem (ES) cells. SDS-PAGE of WERI-RB-1 cell lysate and supernatant from phosphatidylinositol-specific phospholipase C (PI-PLC)-treated WERI-RB-1 cells resulted in the appearance of a prominent 68-kDa band. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI TOF MS) sequence analysis revealed TNAP-specific peptides. Screening of the MSCA-1-specific antibody W8B2 on HEK-293 cells transfected with the full-length coding sequence of TNAP showed specific reactivity with transfected but not with parent cell line. In addition, TNAP-specific mRNA expression was selectively detected in the transfectant line. In agreement with these findings, enzymatic activity of TNAP was exclusively detected in sorted MSCA-1 + BM cells but not in the MSCA-1 − negative fraction. Surface marker analysis revealed coexpression of the embryonic marker SSEA-3 but not SSEA-4, TRA-1-60, and TRA-1-81. In endometrium, TNAP is expressed at intermediate levels on CD146 + cells and at high levels in the luminal space of glandular epithelia. Our results demonstrate that TNAP is a selective marker for the prospective isolation of BM-derived MSC and MSC-like cells in endometrium.